Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDDate | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
06/29/2024 | Q2 2024 | -$0.67 | $0 | |||
03/30/2024 | Q1 2024 | -$0.25 | $0 | |||
12/30/2023 | Q4 2023 | -$1.54 | $0 | |||
09/29/2023 | Q3 2023 | -$2.48 | $0 | |||
06/28/2023 | Q2 2023 | -$0.11 | $0 | |||
03/29/2023 | Q1 2023 | $0.02 | $0 | |||
12/29/2022 | Q4 2022 | -$0.14 | $0 | |||
09/28/2022 | Q3 2022 | $0.04 | $3,000 | |||
06/28/2022 | Q2 2022 | $0.22 | $0 | |||
03/29/2022 | Q1 2022 | $0.09 | $0 | |||
12/29/2021 | Q4 2021 | -$0.06 | $0 | |||
09/28/2021 | Q3 2021 | $0.22 | $0 | |||
06/28/2021 | Q2 2021 | -$0.20 | $0 | |||
03/29/2021 | Q1 2021 | -$0.00 | $0 |
The conference call for NKGen Biotech, Inc. Warrants's latest earnings report can be listened to online.
The conference call transcript for NKGen Biotech, Inc. Warrants's latest earnings report can be read online.
NKGen Biotech, Inc. Warrants (:NKGNW) has a recorded net income of $0. NKGen Biotech, Inc. Warrants has generated $-5.38 earnings per share over the last four quarters.
NKGen Biotech, Inc. Warrants (:NKGNW) has a price-to-earnings ratio of -0.13 and price/earnings-to-growth ratio is 0.01.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED